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We report the case of a 45-year-old woman who palpated a voluminous painless lump 
in the superior outer quadrant of her left breast. Her past medical history revealed an 
acute myeloid leukemia (AML) treated and considered in remission 1 month prior to this 
discovery. Imaging work-up by mammogram, US, and MRI showed multiples masses 
suspect of malignancy in both breasts. US-guided needle biopsy was performed in the 
palpable mass and in one of the multiple lesions located in the right breast. Histologic 
findings were compatible with a granulocytic sarcoma in both breasts, which was con-
sidered as a relapse of the AML treated a few months earlier.
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INtRoDUCtIoN
Granulocytic sarcoma (GS), also known as myeloid sarcoma or chloroma, is a rare extramedullary 
manifestation of myeloid hematological malignancies mostly associated with acute myeloid leuke-
mia (AML). It is characterized by the formation of clinically evident tumors containing immature 
myeloid cells in extramedullary sites, which commonly include the skin, soft tissues, the CNS, and 
the urogenital tract. Although the majority of cases arise in patients with AML, the disease may rarely 
manifest without or prior to medullary involvement (1–6).
Breast GS is very rare and only accounts for approximately 8% of cases (2). Clinical findings are 
non-specific and diagnosis can be very challenging, especially in cases presenting with primary 
breast involvement and no evidence of medullary disease (7, 8).
Despite of its importance for the initial assessment of the disease, breast imaging also lacks speci-
ficity and GS can mimic several other tumors, including breast carcinoma and lymphoma. Moreover, 
only a few reports focusing on radiographic description have been published so far (9–13). Currently, 
only histological examination associated with immunohistochemistry is capable of confirming the 
disease (6, 8, 14).
Here, we report the case of a patient presenting with bilateral multicentric breast GS after a few 
months of confirmed AML remission with special focus on mammographic, sonographic, and MRI 
findings.
Case RepoRt
A 45-year-old woman noticed a sore palpable mass located in the outer upper quadrant of her 
left breast. Clinical examination revealed a painful and hard palpable mass measuring about 
2.5 cm × 2 cm with no associated lymph nodes in the left axilla. Her medical history revealed an 
AML diagnosed 2 years earlier and classified as M4/M5 according to the French–American–British 
classification with FLT3-ITD and NPM1 mutations. No AML1-ETO, CBFb-MYH11, or PML-RARa 
FIGURe 2 | Ultrasound of both breasts demonstrates one of the 
multiple masses located on the right breast (a) which is characterized 
by an oval shape, smooth borders and a hypoechoic appearance.  
The palpable mass located in the upper outer quadrant of the left breast (B) 
presents an irregular shape and borders with posterior shadowing suggestive 
of malignancy.
FIGURe 1 | Mammogram performed with mediolateral oblique 
incidences of both breasts shows multiple oval well-defined masses 
located in the right breast (a) and a round lesion with fine spiculated 
borders located on the superior quadrant of the left breast (B) 
associated with smaller round lesions.
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aberrations were found. Complete remission was demonstrated 
by bone marrow examination after induction chemotherapy 
followed by consolidation chemotherapy with cytarabine and 
idarubicine.
A mammogram was performed with only mediolateral 
oblique incidences because of breast discomfort (Figure  1). It 
showed a round mass with spiculated margins located in the 
superior quadrant measuring approximately 2 cm × 1.8 cm and 
associated with other well-defined oval shaped lesions involving 
both breasts with a size range of 1–2 cm. An ultrasound revealed 
an ill-defined hypoechoic lesion with acoustic shadowing located 
in the outer upper quadrant of the left breast measuring about 
1.9 cm × 1.6 cm and corresponding to the known palpable mass. 
Multiple similar well-defined hypoechoic oval masses were 
observed scattered throughout the remainder of the breasts tissue 
(Figure 2). On MRI, all lesions (Figure 3) including the palpable 
one (Figure  4) were hypointense on T1-weighted images and 
hyperintense on T2-weighted images. After injection of gadolin-
ium-based contrast medium, most lesions demonstrated a faint 
enhancement measuring approximately 1–3  cm. On the other 
hand, the palpable lesion in the left breast demonstrated a “ring” 
enhancement reminiscent of an abscess. The differential diagno-
sis of imaging findings include multicentric breast carcinoma, 
malignant lymphoma, and less likely multiple fibroadenomas.
Lastly, US-guided needle biopsy was performed in the known 
palpable mass and in one of the multiple lesions located in the 
right breast. Histological samples showed dense myeloid cellular 
proliferation with breast tissue invasion. Biopsies were positive 
for myeloperoxydase (MPO), CD68, and CD117, which are mark-
ers for myeloid tumors (Figure  5). Molecular biology analysis 
resulted positive for FLTD3-ITD mutation. Histological features 
were consistent with extramedullary AML of both breasts.
Salvage therapy with azacytidine was initially administered, 
but had to be discontinued because of poor clinical condition 
and development of renal failure. Subsequently, continuous 
treatment with sorafenib was introduced resulting in a rapid 
breast ache relief associated with an excellent renal tolerance. 
Follow-up with breast MRI (Figures  6 and 7) showed partial 
response of the breast disease within 1  month with complete 
resolution of almost all known lesions and absence of new ones: 
only a small fraction of focal contrast enhancements measuring 
up to 1 cm were observed during follow-up (Figure 8). Although 
non-specific, we precautiously considered these focal contrast 
enhancements as malignant since the patient refused a new 
biopsy.
DIsCUssIoN
Granulocytic sarcomas (synonyms: myeloid sarcoma, chloroma) 
are rare extramedullary tumors composed of malignant myeloid 
precursor cells and associated mainly with AML although 
uncommon association with other myeloid malignancies have 
been described. Rarely, it can arise as a primary tumor in patients 
with no past or concurrent history of AML. Historically, the term 
chloroma was coined to describe these tumors because of their 
greenish color (chloros means green in Greek) which is attributed 
to their MPO content (1–5). GS has a slight predilection toward 
males (male-to-female ratio, 1:2), and it typically occurs in the 
FIGURe 4 | on MRI, the palpable mass located in the upper outer left 
quadrant demonstrates a hyperintense signal on t2-weighted images 
with fat saturation (a) and a hypointense signal on t1-weighted 
images (B). After gadolinium administration, the mass shows little 
enhancement and a small necrotic area with enhancing borders (C).
FIGURe 3 | on MRI, multiple round masses are localized in the outer 
upper quadrant of the right breast, which present a hyperintense 
signal on t2-weighted images and fat saturation (a) and a 
hypointense signal on t1-weighted images (B). These lesions present a 
faint contrast enhancement on gadolinium-enhanced T1-weighted images 
with fat saturation (C).
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later decades of life even though cases have been described in 
nearly every age group (1–3).
Granulocytic sarcoma affects 2.5–9.1% of patients with 
AML (1) and can virtually arise in any part of the human body. 
Most common described sites include the skin, lymph nodes, 
soft tissues, bones, the CNS, and the urogenital tract (1–6); 
however, there is some discordancy in the literature when it 
comes to describing its typical locations. Breast involvement is 
rare, especially isolated disease. A historical retrospective study 
in patients with myelogenous leukemia from Hiroshima and 
Nagasaki (2) depicted breast involvement in approximately 8% 
of cases. In recent reviews, 153 cases of breast GS have been 
reported from 1969 to 2005 according to Cunningham (7) and 
139 cases between 1980 and 2010 according to Surov et  al. 
(8). In both reviews, most cases were associated with AML, 
especially as intramammary relapse after therapy, and only a 
small fraction of these (around 17%) showed isolated breast 
disease although the majority developed medullary disease 
somewhere between 1 and 2  years after breast GS diagnosis. 
Curiously, there is a considerable higher prevalence among 
females, especially in the pre-menopausal population (90% of 
cases) (7) in spite of the fact that GS is slightly more prevalent 
among males suggesting some tropism for the more developed 
breast tissue which might be independent from classical pre-
disposing factors.
Clinical findings are non-specific and may mimic primary 
breast cancer. It often manifests as palpable breast nodules 
that can be either painful or painless and that can involve 
both breasts. Some may present with skin involvement and/
or enlarged axillary lymph nodes. Usually, no nipple retraction 
or discharge is observed (7–9, 15). As in our case, a thorough 
investigation of the patient’s medical records is the key for the 
diagnosis.
Similarly, imaging findings are non-specific, and a low index 
of suspicion must be kept in mind in patients presenting with 
breast masses and with a history of hematological neoplasia. Only 
a few mammogram descriptions exist in the literature (9–11). 
They usually report non-calcified masses of variable size with 
hazy and indistinct borders, which can be confused with others 
FIGURe 6 | Follow-up with MRI shows significant decrease in tumor 
burden with no evidence of new lesions. A complete response was 
achieved in most lesions and observed by the absence of contrast 
enhancement especially in the big cluster of oval masses of the right breast 
(arrow). T2-weighted images with fat saturation (a); T1-weighted images  
(B); gadolinium-enhanced T1-weighted images with fat saturation (C).
FIGURe 5 | Dense myeloid precursor proliferation with breast tissue invasion. Immunostaining is positive for myeloperoxydase, CD68 and CD117, which are 
markers for myeloid cells.
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malignant breast tumors. Likewise, ultrasound evaluation can be 
misleading and only a few descriptions have been published so 
far (9, 10, 12). Generally, lesions are depicted as hypoechoic with 
microlobulations or spiculated margins. Sometimes it can show 
prominent vascularity on color Doppler. Unlike mammogram, 
ultrasound is particularly interesting for younger patients because 
of the relatively larger fibroglandular-to-fat ratio and the lack of 
ionizing radiation (12).
On MRI, the lesions normally demonstrate a variable degree 
of contrast enhancement and are usually hyperintense on 
T2-weighted images and iso- to hypointense on T1-weighted 
images (10, 13). In our case, contrast-enhanced images showed a 
small area of necrosis in the center surrounded by a faint periph-
eral enhancement in the palpable sore lesion, which is a common 
finding in other GS locations making it sometimes difficult to 
distinguish from abscesses (6). Since this particular lesion was 
painful, there might be some correlation between the presence of 
necrosis and the clinical features.
Differential diagnosis depends greatly on the age of the 
patient and on the onset of the medullary disease. Based solely 
on imaging, younger patients tend to present with benign breast 
masses such as fibroadenomas and fibrocystic changes. Less 
common benign lesions include papilloma, hemangioma, and 
intramammary lymph nodes. More rarely, malignant lesions such 
as lymphoma and soft tissue sarcomas may be found but those 
seem to be even rarer than primary breast carcinoma in this age 
population (12). In older women, the most important differential 
to bear in mind remains primary breast carcinoma, especially 
multicentric. Secondarily, breast lymphoma and benign lesions 
must be considered (6, 10–13).
Final diagnosis is based on histological analysis, which 
shows tumor cells with evidence of variable degrees of myeloid 
FIGURe 8 | Gadolinium-enhanced t1-weighted images with fat 
saturation showing a remaining 1-cm focal enhancement 1 month 
after therapy (arrow).
FIGURe 7 | Here, we observe a complete response of the known 
palpable lesion in the left breast with absence of contrast 
enhancement (arrow). T2-weighted images with fat saturation (a); 
T1-weighted images (B); gadolinium-enhanced T1-weighted images  
with fat saturation (C).
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differentiation. Conventional histological features can be 
inconstant, therefore misdiagnosis may occur, particularly in 
poorly differentiated tumors and in patients presenting with 
isolated disease. GS can mimic a considerable number of other 
malignancies but in the breast the main misdiagnosis includes 
non-Hodgkin’s lymphoma (especially large-cell and Burkitt 
lymphomas), sarcoma, and primary breast carcinoma (especially 
infiltrating lobular carcinoma) (15). In order to avoid or to reduce 
this issue, cytogenetic and immunohistochemical techniques as 
well as flow cytometry are extremely useful (15). These include 
a vast array of markers which are more or less specific for GS 
(i.e., MPO, lysozyme, CD68, CD117, etc.), and the combination 
of two or more helps distinguishing from lymphoma (5, 14, 15). 
The most common cytogenetic and biochemical abnormalities 
include t(8; 21), inv (16), and cytoplasmic expression of NPM and 
FLT3-ITD (13). Interestingly, some of these mutations may carry 
a prognostic value (3, 5, 14).
The mainstay of treatment is systemic chemotherapy with 
regimens normally used for AML. Several studies and reviews 
have highlighted the importance of early systemic therapy in 
order to achieve a long disease-free survival and to avoid AML 
development or relapse (3–5, 7, 14). There is a lack of clear indica-
tion for combination with radiotherapy since survival rates seem 
to be equivalent, although it might be a useful tool for sympto-
matic relief or in refractory disease. Moreover, a few retrospective 
studies have shown a high rate of AML development in patients 
with isolated GS undergoing radiotherapy or surgery alone. There 
is no clear consensus if whether or not bone marrow transplan-
tation has an impact even though recent studies have shown a 
significant survival benefit (4, 5, 14). Finally, promising targeted 
therapies currently in trial for AML, such as FLT3 inhibitors, 
farnesyl-transferase inhibitors and histone deacetylase inhibitors 
might be an effective option against GS (4).
The prognostic value of patients developing GS in the context 
of AML is somewhat debatable although the historical consensus 
is that survival is poorer in this population. Other factors must 
be considered before assessing prognosis, such as cytogenetic 
profiles and age of onset (4, 5, 14). Conversely, some studies have 
shown a better prognosis in isolated disease without medullary 
involvement (4, 14).
CoNCLUsIoN
Granulocytic sarcoma of the breast is a rare extramedullary 
manifestation of AML and other hematologic diseases and some-
times can develop without or prior to medull ary involvement. 
The absence of specific mammographic, sonographic, and MRI 
features can be very challenging for even the most experienced 
radiologist. Therefore, a detailed review of the patient’s medical 
history combined with a low index of suspicion is crucial for 
guiding toward the proper diagnostic procedures. These include 
histological examinations with ancillary techniques that are 
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paramount to confirm the diagnosis and to assist in planning the 
subsequent treatment.
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